REG - Hutchmed China Ltd - Directorate change

HUTCHMED (China)Announcement

06/03/2026 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260306:nRSF5554Va&default-theme=true

RNS Number : 5554V  Hutchmed (China) Limited  06 March 2026

Intended Retirement of Independent Non-executive Director and changes of
composition of board committees

 

Hong Kong, Shanghai & Florham Park, NJ  - Friday, March 6, 2026: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has
informed the Company that he would not seek re-election after retiring from
the Board at the forthcoming annual general meeting of the Company to be held
on May 12, 2026 ("AGM").  Professor Mok has served as an Independent
Non-executive Director of the Company for more than eight years, approaching
the nine-year cap on the tenure of independent non-executive directors under
the Hong Kong Listing Rules.  Consequently, he will cease to be an
Independent Non-executive Director of the Company at the conclusion of the
AGM.  Upon his retirement, he will also step down from his roles as chairman
and member of the board committees of the Company.

 

In connection with the intended retirement of Professor Mok from the Board,
the Board has approved the following changes to the composition of the board
committees and the Senior and Lead Independent Non-executive Director of the
Company, effective from the conclusion of the AGM, subject to the respective
Directors being re-elected as Directors by the shareholders at the AGM:-

 

(1)        Dr Renu Bhatia will be appointed as the Senior and Lead
Independent Non-executive Director, and appointed on the Nomination Committee
as the chairman;

(2)        Dr Chaohong Hu will be appointed as the chairman of the
Technical Committee; and

(3)        Professor Tan Shao Weng, Daniel will be appointed as a
member of the Sustainability Committee.

 

Each of Dr Bhatia, Dr Hu and Professor Tan is currently an Independent
Non-executive Director of the Company.

 

Dr Dan Eldar, the Chairman of HUTCHMED, said: "Professor Mok has served with
distinction as an Independent Non-executive Director and as chairman of both
the Nomination Committee and the Technical Committee. His leadership has been
instrumental in strengthening the Board composition, and guiding the
scientific and clinical development programs. His internationally recognized
expertise in oncology has brought invaluable perspective to the long term
strategy of the Company. The Board sincerely thanks Professor Mok for his
significant contributions to the growth of the Company, and we wish him all
the best in his future endeavours."

 

Pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules,
Professor Mok has confirmed that he has no disagreement with the Board and
that there are no other matters that need to be brought to the attention of
the shareholders of the Company in connection with his retirement from the
Board.

 

About HUTCHMED
 
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/)
 or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/)
.

 

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events. Forward-looking statements involve risks
and uncertainties. Such risks and uncertainties include, among other things,
the risk that current or future appointees to HUTCHMED's board of directors
are not effective in their respective positions, the difficulty in locating
and recruiting suitable candidates for its board of directors and the
management difficulties which may arise from changes in HUTCHMED's board of
directors. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the US Securities and Exchange Commission, on AІM and with The
Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to
update or revise the information contained in this announcement, whether as a
result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

 

 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
     Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABSGDXBUGDGLU



            Copyright 2019 Regulatory News Service, all rights reserved